key: cord-0751582-k8cz0nq3
authors: Guglielmelli, Paola; Mazzoni, Alessio; Maggi, Laura; Kiros, Seble Tekle; Zammarchi, Lorenzo; Pilerci, Sofia; Rocca, Arianna; Spinicci, Michele; Borella, Miriam; Bartoloni, Alessandro; Rossolini, Gian Maria; Annunziato, Francesco; Vannucchi, Alessandro M.
title: Impaired response to first SARS‐CoV‐2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib
date: 2021-08-12
journal: Am J Hematol
DOI: 10.1002/ajh.26305
sha: 5f52e50b2c7ed0533549580f3650acb06dc01c79
doc_id: 751582
cord_uid: k8cz0nq3

nan

To the Editor:

Covid-19, the disease caused by pandemic SARS-CoV-2 infection, had significant impact on patients with hematologic conditions 1 ; a metaanalysis involving 3377 patients with hematologic malignancies who were affected by Covid-19 reported a mortality rate of 34%. 2 A similarly dismal outcome was documented among 175 patients with chronic myeloproliferative neoplasms (MPN), collected in a European observational study, where mortality rate was 30% for the entire cohort, reaching 48% in primary overt myelofibrosis (MF). 3 Covid-19 was also associated with higher incidence of thrombosis in patients with essential thrombocythemia (ET), compared to MF and polycythemia vera (PV) (20% vs 5% for both, respectively). 4 Finally, MPN patients surviving the acute phase may suffer from additional long-term sequelae from Covid-19, that furtherly increase mortality and morbidity. 5 The JAK1 and JAK2 inhibitor (JAKi) ruxolitinib is approved for the treatment of patients with MF and hydroxyurea resistant/refractory PV. 6 By inhibiting JAK-STAT signaling, ruxolitinib has profound effects on different cell compartments of the immune system, including T cells, natural killer and dendritic cells, in addition to potently dampening inflammatory cytokine production. 7 These properties have been mechanistically linked to the increased rate of infections in MPN patients receiving ruxolitinib, and, conversely, were explored successfully in the setting of steroid-refractory acute graft vs host disease following allogeneic stem cell transplantation. 8 In the above cited European study in MPN, rapid discontinuation of the drug was implicated in 75% of deaths occurring in the ruxolitinib-treated cohort; these were ascribed to a previously described "discontinuation syndrome", a potentially fatal complication due to a cytokine storm that follows the abrupt suspension of ruxolitinib. 9, 10 In fact, observational studies support the effectiveness of ruxolitinib to quench the hyper inflammatory reaction accompanying Covid-19 in the general population. 11, 12 Due to the immunomodulatory properties of ruxolitinib, the question arises whether response to vaccination for SARS-CoV-2 in patients under stable ruxolitinib therapy might be impaired. Table S1 . (Figure 1(A)-(C) ), was significantly lower in ruxo-patients compared to healthy controls and the no-ruxo group.

The latter conversely did not differ significantly from controls, suggesting that the potentiality to mount adequate immune response is maintained in most MPN patients who were not receiving ruxolitinib. In detail, mean anti-S BAU levels/ml were 111.4, 513.4 and 510.8 for ruxo, no-ruxo and controls, respectively ( Figure 1(A) ); corresponding anti-RBD BAU levels/mL were 65.2, 631.7 and 254.2 (Figure 1(B) ); and, for neutralizing antibodies, the mean relative index was 1.1, 3.5 and 3.8 (Figure 1(C) ). All these values were statistically different when comparing ruxo patients vs no-ruxo and controls, but not between controls and no-ruxo patients (p values are reported in Figure 1(A)-(C) ).

According to the predefined cut-off levels, all the 14 healthy volunteers were considered as responders to vaccination for the anti-S IgG, anti RBD IgG and neutralizing antibodies (100% each), compared to 38.8%, 33.3% and 33.3%, respectively, for the ruxo-patients (p < 0.001 vs controls for each antibody type), and 91.6% (p = not significant), 91.6% (p = not significant) and 58.3% (p = < 0.01) in the no-ruxo group ( Figure 1(D)-(F) ).

In summary, these findings, with the limitation of the small number of subjects included, make a strong and urgent argument for an impaired early response to SARS-CoV-2 vaccine in patients receiving ruxolitinib.

Further and future studies are needed to address whether such unresponsive status persists after the second dose of vaccine, as suggested by a study performed in Israel, where the rate of seropositivity (anti-S1/ S2 IgG) after complete vaccination in patients with MPN was 42% for those using JAKi. 13 It will be important to address whether also responses mediated by T-cell and other myeloid cells are impaired by ruxolitinib treatment, owing to their key role in SARS-CoV-2 infection. [14] [15] [16] Although clear-cut relationships between specific anti-SARS-F I G U R E 1 Serum levels of (A) anti-Spike IgG, (B) anti-RBD IgG, (C) neutralizing antibodies in 18 ruxolitinib-treated MPN patients (black diamonds), 12 no-ruxolitinib treated MPN patients (red diamonds), 14 healthy controls (blue diamonds), before the first (T0) or the second (T1) vaccine dose administration. Horizontal lines represent mean values. Gray area represent cut-off value. Data in A,B are expressed as binding antibody unit (BAU)/mL, while in C as Index. **p < 0.01; ***p < 0.01 calculated with Mann-Whitney test. Percentage of ruxolitinib-treated (R), no-ruxolitinib-treated (N-R) MPN patients or healthy subjects (H) who developed antibodies D, (anti-S IgG, anti-RBD IgG, E, or neutralizing antibodies, F,) above (black, "responder") or below (gray, "non-responder") the predetermined cut-off levels

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and metaanalysis of 3377 patients

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19

Long-term follow-up of recovered MPN patients with COVID-19

The safety of JAK kinase inhibitors for the treatment of myelofibrosis

Immunological consequences of JAK inhibition: friend or foe?

Ruxolitinib in corticosteroidrefractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis

A life-threatening ruxolitinib discontinuation syndrome

Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation

BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies

Cell-mediated and humoral adaptive immune responses to SARS-CoV-2 are lower in asymptomatic than symptomatic COVID-19 patients

Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent

Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity